Nanoparticle-based drug delivery systems have emerged as promising platforms for enhancing therapeutic efficacy while minimizing off-target effects. Among various strategies employed to optimize these systems, polyethylene glycol (PEG) modification, known as PEGylation—the covalent attachment of PEG to nanoparticles, has gained considerable attention for its ability to impart stealth properties to nanoparticles while also extending circulation time and improving biocompatibility. PEGylation extends to different drug delivery systems, in specific, nanoparticles for targeting cancer cells, where the concentration of drug in the cancer cells is improved by virtue of PEGylation. The primary challenge linked to PEGylation lies in its confirmation. Numerous research findings provide comprehensive insights into selecting PEG for various PEGylation methods. In this review, we have endeavored to consolidate the outcomes concerning the choice of PEG and diverse PEGylation techniques.
Get full access to this article
View all access options for this article.
References
1.
AggarwalP, HallJB, McLelandCB, et al.Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev, 2009; 61(6):428–437; doi: 10.1016/j.addr.2009.03.009
2.
PartikelK, KorteR, SteinNC, et al.Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles. Eur J Pharm Biopharm, 2019; 141:70–80; doi: 10.1016/j.ejpb.2019.05.006
3.
MozarFS, ChowdhuryEH. Impact of PEGylated nanoparticles on tumor targeted drug delivery. Curr Pharm Des, 2018; 24(28):3283–3296; doi: 10.2174/1381612824666180730161721
4.
AlayoubiA, AlqahtaniS, KaddoumiA, et al.Effect of PEG surface conformation on anticancer activity and blood circulation of Nanoemulsions loaded with tocotrienol-rich fraction of palm oil. Aaps J, 2013; 15(4):1168–1179; doi: 10.1208/s12248-013-9525-z
5.
RenH, HeY, LiangJ, et al.Role of Liposome Size, Surface Charge, and PEGylation on Rheumatoid Arthritis Targeting Therapy. ACS Appl Mater Interfaces, 2019; 11(22):20304–20315; doi: 10.1021/acsami.8b22693
6.
DemirelE, KaracaE, DurmazYY. Effective PEGylation method to improve biocompatibility of graphene derivatives. Eur Polym J, 2020; 124:109504; doi: 10.1016/j.eurpolymj.2020.109504
7.
AnabousiS, KleemannE, BakowskyU, et al.Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J Nanosci Nanotechnol, 2006; 6(9):3010–3016; doi: 10.1166/jnn.2006.461
8.
SelliD, MottaS, Di ValentinC. Impact of surface curvature, grafting density and solvent type on the PEGylation of titanium dioxide nanoparticles. J Colloid Interface Sci, 2019; 555:519–531; doi: 10.1016/j.jcis.2019.07.106
9.
SchöttlerS, BeckerG, WinzenS, et al.Protein adsorption is required for stealth effect of poly (ethylene glycol)-and poly (phosphoester)-coated nanocarriers. Nature Nanotech, 2016; 11(4):372–377; doi: 10.1038/NNANO.2015.330
10.
MotlaqVF, KnudsenKD, NyströmB. Effect of PEGylation on the stability of thermoresponsive nanogels. J Colloid Interface Sci, 2018; 524:245–255; doi: 10.1016/j.jcis.2018.04.024
11.
KelleyWJ, FromenCA, Lopez-CazaresG, et al.PEGylation of model drug carriers enhances phagocytosis by primary human neutrophils. Acta Biomater, 2018; 79:283–293; doi: 10.1016/j.actbio.2018.09.001
12.
NgouneR, PetersA, von ElverfeldtD, et al.Accumulating nanoparticles by EPR: A route of no return. J Controlled Release, 2016; 238:58–70; doi: 10.1016/j.jconrel.2016.07.028
13.
FangJ, NakamuraH, MaedaH. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev, 2011; 63(3):136–151; doi: 10.1016/j.addr.2010.04.009
14.
SwierczewskaM, LeeKC, LeeS. What is the future of PEGylated therapies? Expert Opin Emerg Drugs, 2015; 20(4):531–536; doi: 10.1517/14728214.2015.1113254
15.
BhartiS, KaurG, GuptaS, et al.PEGylation of CdSe/ZnS core/shell nanoparticles and its behavior at different pH. J Lumin, 2017; 181:459–466; doi: 10.1016/j.jlumin.2016.09.005
16.
AwadNS, PaulV, MahmoudMS, et al.Effect of pegylation and targeting moieties on the ultrasound-mediated drug release from liposomes. ACS Biomater Sci Eng, 2020; 6(1):48–57; doi: 10.1021/acsbiomaterials.8b01301
17.
MillaP, DosioF, CattelL. PEGylation of proteins and liposomes: A powerful and flexible strategy to improve the drug delivery. Curr Drug Metab, 2012; 13(1):105–119; doi: 10.2174/138920012798356934
18.
LolloG, Rivera-RodriguezGR, BejaudJ, et al.Polyglutamic acid–PEG nanocapsules as long circulating carriers for the delivery of docetaxel. Eur J Pharm Biopharm, 2014; 87(1):47–54; doi: 10.1016/j.ejpb.2014.02.004
19.
KeckCM, JanschM, MüllerRH. Protein adsorption patterns and analysis on IV nanoemulsions—the key factor determining the organ distribution. Pharmaceutics, 2012; 5(4):36–68; doi: 10.3390/pharmaceutics5010036
20.
Torcello-GómezA, Wulff-PérezM, Gálvez-RuizMJ, et al.Block copolymers at interfaces: Interactions with physiological media. Adv. Colloid Interf. Sci, 2014; 206:414–427; doi: 10.1016/j.cis.2013.10.027
21.
VeroneseFM, MeroA. The impact of PEGylation on biological therapies. BioDrugs, 2008; 22(5):315–329.
22.
OwensDE, PeppasNA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm, 2006; 307(1):93–102; doi: 10.1016/j.ijpharm.2005.10.010
23.
ĐokovićJB, SavićSM, MitrovićJR, et al.Curcumin loaded PEGylated nanoemulsions designed for maintained antioxidant effects and improved bioavailability: A pilot Study on Rats. Int J Mol Sci, 2021; 22(15):7991; doi: 10.3390/ijms22157991
24.
FrechesD, PatilHP, FrancoMM, et al.PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’antibody fragment after pulmonary delivery in three different species. Int J Pharm, 2017; 521(1-2):120–129; doi: 10.1016/j.ijpharm.2017.02.021
25.
ChengY, LiuM, HuH, et al.Development, optimization, and characterization of PEGylated Nanoemulsion of prostaglandin E1 for long circulation. AAPS PharmSciTech, 2016; 17(2):409–417; doi: 10.1208/s12249-015-0366-1
26.
JinM, JinG, HuangW, GaoZ. Z. PEGylation of lumbrokinase improves pharmacokinetic profile and enhances anti-thrombotic effect in a rat carotid artery thrombosis model. Mol Med Rep, 2017; 16(4):4909–4914; doi: 10.3892/mmr.2017.7171
27.
DevalapallyH, ZhouF, McDadeJ, et al.Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds. Drug Deliv, 2015; 22(4):467–474; doi: 10.3109/10717544.2013.869275
28.
TakeuchiI, OnakaH, MakinoK. Biodistribution of colloidal gold nanoparticles after intravenous injection: Effects of PEGylation at the same particle size. Biomed Mater Eng, 2018; 29(2):205–215.
29.
DingW, MinamikawaH, KametaN, et al.Effects of PEGylation on the physicochemical properties and in vivo distribution of organic nanotubes. IJN, 2014:5811; doi: 10.2147/IJN.S75604
30.
KouchakzadehH, ShojaosadatiSA, MaghsoudiA, et al.Optimization of PEGylation conditions for bsa nanoparticles using response surface methodology. AAPS PharmSciTech, 2010; 11(3):1206–1211.
31.
KimCH, SaCK, GohMS, et al.DOI. pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: Design and in vitro evaluation. Int J Nanomedicine, 2018; 13:6661–6675; doi: 10.2147/IJN.S184355
32.
PetersJT, VergheseS, SubramanianD, et al.Surface hydrolysis-mediated PEGylation of poly (N-isopropyl acrylamide) based nanogels. Regen Biomater, 2017; 4(5):281–287; doi: 10.1093/rb/rbx022
HuY, ZhaoZ, HarmonT, et al.Paradox of PEGylation in fabricating hybrid nanoparticle-based nicotine vaccines. Biomaterials, 2018; 182:72–81; doi: 10.1016/j.biomaterials.2018.08.015
35.
LinJ, ZhangH, MorovatiV, et al.PEGylation on mixed monolayer gold nanoparticles: Effect of grafting density, chain length, and surface curvature. J Colloid Interface Sci, 2017; 504:325–333; doi: 10.1016/j.jcis.2017.05.046
36.
KhanB, NawazM, PriceGJ, et al.In vitro sustained release of gallic acid from the size-controlled PEGylated magnetite nanoparticles. Chem Pap, 2021; 75(10):5339–5352.
37.
ElsewedyHS, AldhubiabBE, MahdyMA, et al.Brucine PEGylated nanoemulsion: In vitro and in vivo evaluation. Colloids Surf Physicochem Eng Asp, 2021; 608:125618; doi: 10.1016/j.colsurfa.2020.125618
38.
KoideH, SuzukiH, OchiaiH, et al.Enhancement of target toxin neutralization effect in vivo by PEGylation of multifunctionalized lipid nanoparticles. Biochem Biophys Res Commun, 2021; 555:32–39; doi: 10.1016/j.bbrc.2021.03.073
39.
RobertsMJ, BentleyMD, HarrisJM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev, 2002; 54(4):459–476; doi: 10.1016/S0169-409X(02)00022-4
40.
Santander-OrtegaMJ, Plaza-OliverM, Rodríguez-RobledoV, et al.PEGylated nanoemulsions for oral delivery: Role of the inner core on the final fate of the formulation. Langmuir, 2017; 33(17):4269–4279; doi: 10.1021/acs.langmuir.7b00351
41.
ReichertC, BorchardG. Noncovalent PEGylation, an innovative subchapter in the field of protein modification. J Pharm Sci, 2016; 105(2):386–390; doi: 10.1002/jps.24692
42.
KolateA, BaradiaD, PatilS, et al.PEG—A versatile conjugating ligand for drugs and drug delivery systems. J Controlled Release, 2014; 192:67–81; doi: 10.1016/j.jconrel.2014.06.046
43.
MuellerC, CapelleMA, ArvinteT, et al.Noncovalent pegylation by dansyl-poly (ethylene glycol) s as a new means against aggregation of salmon calcitonin. J Pharm Sci, 2011; 100(5):1648–1662; doi: 10.1002/jps.22401
44.
MuellerC, CapelleMA, ArvinteT, et al.Tryptophan-mPEGs: Novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation. Eur J Pharm Biopharm, 2011; 79(3):646–657; doi: 10.1016/j.ejpb.2011.06.003
45.
MuellerC, CapelleMA, SeyrekE, et al.Noncovalent PEGylation: Different effects of dansyl-, l-tryptophan–, phenylbutylamino-, benzyl-and cholesteryl-PEGs on the aggregation of salmon calcitonin and lysozyme. J Pharm Sci, 2012; 101(6):1995–2008; doi: 10.1002/jps.23110
46.
KhondeeS, OlsenCM, ZengY, et al.Noncovalent PEGylation by polyanion complexation as a means to stabilize keratinocyte growth factor-2 (KGF-2). Biomacromolecules, 2011; 12(11):3880–3894; doi: 10.1021/bm2007967
47.
KurinomaruT, ShirakiK. Noncovalent PEGylation of L-asparaginase using PEGylated polyelectrolyte. J Pharm Sci, 2015; 104(2):587–592; doi: 10.1002/jps.24217
48.
HermanS, HooftmanG, SchachtE. Poly(Ethylene Glycol) with reactive endgroups: I. modification of proteins. J Bioact Compat Polym, 1995; 10(2):145–187; doi: 10.1177/088391159501000205
49.
JananiSK, DhanabalSP, SureshkumarR, et al.PEGylation of nanoemulsion using spontaneous emulsification method. Assay Drug Dev Technol, 2022; 20(6):274–285; doi: 10.1089/adt.2022.058
50.
ZhenS, LiX. Liposomal delivery of CRISPR/Cas9. Cancer Gene Ther, 2020; 27(7–8):515–527.
51.
HashibaK, SatoY, HarashimaH. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes. J Controlled Release, 2017; 262:239–246; doi: 10.1016/j.jconrel.2017.07.046
52.
LiM, JiangS, SimonJ, et al.Brush conformation of polyethylene glycol determines the stealth effect of Nanocarriers in the low protein adsorption regime. Nano Lett, 2021; 21(4):1591–1598; doi: 10.1021/acs.nanolett.0c03756
53.
NagOK, AwasthiV. Surface engineering of liposomes for stealth behavior. Pharmaceutics, 2013; 5(4):542–569; doi: 10.3390/pharmaceutics5040542
54.
ImmordinoML, DosioF, CattelL. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine, 2006; 1(3):297–315.
55.
De GennesP. Conformations of polymers attached to an interface. Macromolecules, 1980; 13(5):1069–1075; doi: 10.1021/ma60077a009
56.
GarbuzenkoO, BarenholzY, PrievA. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids, 2005; 135(2):117–129; doi: 10.1016/j.chemphyslip.2005.02.003
57.
QuanH, ParkHC, KimY, et al.Modulation of the anti‐inflammatory effects of phosphatidylserine‐containing liposomes by PEGylation. J Biomed Mater Res A, 2017; 105(5):1479–1486; doi: 10.1002/jbm.a.35981
58.
YazdiJR, TafaghodiM, SadriK, et al.Folate targeted PEGylated liposomes for the oral delivery of insulin: In vitro and in vivo Studies. Colloids Surf B Biointerfaces, 2020; 194:111203; doi: 10.1016/j.colsurfb.2020.111203
59.
TangS, GaoD, ZhaoT, et al.An evaluation of the anti-tumor efficacy of oleanolic acid-loaded PEGylated liposomes. Nanotechnology, 2013; 24(23):235102; doi: 10.1088/0957-4484/24/23/235102
60.
TogamiK, MarutaY, NanbuM, et al.Prolonged distribution of aerosolized PEGylated liposomes in the lungs of mice with bleomycin-induced pulmonary fibrosis. Drug Dev Ind Pharm, 2020; 46(11):1873–1880; doi: 10.1080/03639045.2020.1825473
61.
XuL, WangW, ShengYC, et al.PHARMACOKINETICS: Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in chinese patients with breast tumours: PK and the relation to toxicity of PLD in Chinese patients. J Clin Pharm Ther, 2010; 35(5):593–601; doi: 10.1111/j.1365-2710.2009.01128.x
62.
DadashzadehS, ValiAM, RezaieM. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm, 2008; 353(1–2):251–259; doi: 10.1016/j.ijpharm.2007.11.030
63.
RangsimawongW, OpanasopitP, RojanarataT, et al.Skin transport of hydrophilic compound-loaded PEGylated lipid nanocarriers: Comparative study of liposomes, niosomes, and solid lipid nanoparticles. Biol Pharm Bull, 2016; 39(8):1254–1262; doi: 10.1248/bpb.b15-00981
64.
HongM, ZhuS, JiangY, et al.Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Controlled Release, 2009; 133(2):96–102; doi: 10.1016/j.jconrel.2008.09.005
65.
NishaR, KumarP, GautamAK, et al.Assessments of in vitro and in vivo antineoplastic potentials of β-sitosterol-loaded PEGylated niosomes against hepatocellular carcinoma. J Liposome Res, 2021; 31(3):304–315; doi: 10.1080/08982104.2020.1820520
66.
GhaffariM, KalantarSM, HematiM, et al.Co-delivery of miRNA-15a and miRNA-16–1 using cationic PEGylated niosomes downregulates Bcl-2 and induces apoptosis in prostate cancer cells. Biotechnol Lett, 2021; 43(5):981–994.
67.
HeRX, YeX, LiR, et al.PEGylated niosomes-mediated drug delivery systems for Paeonol: Preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. J Liposome Res, 2017; 27(2):161–170; doi: 10.1080/08982104.2016.1191021
68.
ChaudhariD, KucheK, YadavV, et al.Exploring paclitaxel-loaded adenosine-conjugated PEGylated PLGA nanoparticles for targeting triple-negative breast cancer. Drug Deliv Transl Res, 2023; 13(4):1074–1087.
69.
PalmaG, ConteC, BarbieriA, et al.Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer. Int J Pharm, 2014; 473(1–2):55–63; doi: 10.1016/j.ijpharm.2014.06.058
70.
DoddapaneniR, PatelK, OwaidIH, et al.Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug Deliv, 2016; 23(4):1232–1241; doi: 10.3109/10717544.2015.1124472
71.
ZhaoX, TianK, ZhouT, et al.PEGylated multi-walled carbon nanotubes as versatile vector for tumor-specific intracellular triggered release with enhanced anti-cancer efficiency: Optimization of length and PEGylation degree. Colloids Surf B Biointerfaces, 2018; 168:43–49; doi: 10.1016/j.colsurfb.2018.02.041
72.
ShaviGV, ReddyMS, RaghavendraR, et al.PEGylated liposomes of anastrozole for long-term treatment of breast cancer: In vitro and in vivo evaluation. J Liposome Res, 2016; 26(1):28–46; doi: 10.3109/08982104.2015.1029493
73.
HaggagYA, IbrahimRR, HafizAA. Design, formulation and in vivo Evaluation of Novel honokiol-loaded pegylated plga nanocapsules for treatment of breast cancer. Int J Nanomedicine, 2020; 15:1625–1642; doi: 10.2147/IJN.S241428
74.
KhanMT, UddinZ, JavedMA, et al.PEGylated protamine letrozole nanoparticles: A promising strategy to combat human breast cancer via MCF-7 cell lines. Biomed Res Int, 2022; 2022:4438518; doi: 10.1155/2022/4438518
75.
CibotaruS, NastasaV, SanduAI, et al.Pegylation of phenothiazine—A synthetic route towards potent anticancer drugs. J Adv Res, 2022; 37:279–290; doi: 10.1016/j.jare.2021.07.003
76.
WangL, HongY, MaJ, et al.Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis. J Int Med Res, 2020; 48(8):300060520944310; doi: 10.1177/0300060520944310
77.
BobdeY, PatelT, PaulM, et al.PEGylated N-(2 hydroxypropyl) methacrylamide polymeric micelles as nanocarriers for the delivery of doxorubicin in breast cancer. Colloids Surf B Biointerfaces, 2021; 204:111833; doi: 10.1016/j.colsurfb.2021.111833
78.
ShahbazianS, AkbarzadehA, TorabiS, et al.Anti-cancer activity of pegylated liposomal trans-anethole on breast cancer cell lines MCF-7 and T47D. Biotechnol Lett, 2015; 37(7):1355–1359.
79.
GlassJE. Water‐soluble polymers. Kirk‐Othmer Encyclopedia of Chemical Technology. 2000 Dec 4.
80.
YanW, DivandariM, RosenboomJG, et al.Design and characterization of ultrastable, biopassive and lubricious cyclic poly (2-alkyl-2-oxazoline) brushes. Polym Chem, 2018; 9(19):2580–2589; doi: 10.1039/C7PY02137B
81.
LühmannT, SchmidtM, LeiskeMN, et al.Site-specific POxylation of Interleukin-4. ACS Biomater Sci Eng, 2017; 3(3):304–312; doi: 10.1021/acsbiomaterials.6b00578
82.
ViegasTX, BentleyMD, HarrisJM, et al.Polyoxazoline: Chemistry, properties, and applications in drug delivery. Bioconjugate Chem, 2011; 22(5):976–986; doi: 10.1021/bc200049d
83.
KonradiR, AcikgozC, TextorM. Polyoxazolines for nonfouling surface coatings—A Direct Comparison to the Gold Standard PEG. Macromol Rapid Commun, 2012; 33(19):1663–1676; doi: 10.1002/marc.201200422
84.
PidhatikaB, RodensteinM, ChenY, et al.Comparative stability studies of poly (2-methyl-2-oxazoline) and poly (ethylene glycol) brush coatings. Biointerphases, 2012; 7(1-4):1; doi: 10.1007/s13758-011-0001-y
85.
Van KuringenHP, LenoirJ, AdriaensE, et al.Partial hydrolysis of poly (2‐ethyl‐2‐oxazoline) and potential implications for biomedical applications? Macromol Biosci, 2012; 12(8):1114–1123; doi: 10.1002/mabi.201200080
86.
UlbrichtJ, JordanR, LuxenhoferR. On the biodegradability of polyethylene glycol, polypeptoids and poly (2-oxazoline) s. Biomaterials, 2014; 35(17):4848–4861; doi: 10.1016/j.biomaterials.2014.02.029
87.
BludauH, CzaparAE, PitekAS, et al.POxylation as an alternative stealth coating for biomedical applications. Eur Polym J, 2017; 88:679–688; doi: 10.1016/j.eurpolymj.2016.10.041
88.
SedlacekO, MonneryBD, FilippovSK, et al.Poly(2‐Oxazoline)s—Are they more advantageous for biomedical applications than other polymers? Macromol Rapid Commun, 2012; 33(19):1648–1662; doi: 10.1002/marc.201200453
MeroA, PasutG, ViaLD, et al.Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: Suitable alternatives to PEG-conjugates? J Controlled Release, 2008; 125(2):87–95; doi: 10.1016/j.jconrel.2007.10.010
91.
FarkašP, KorcováJ, KronekJ, et al.Preparation of synthetic polyoxazoline based carrier and Vibrio cholerae O-specific polysaccharide conjugate vaccine. Eur J Med Chem, 2010; 45(2):795–799; doi: 10.1016/j.ejmech.2009.11.002
92.
SoeZC, OuW, GautamM, et al.Development of Folate-functionalized PEGylated Zein nanoparticles for ligand-directed delivery of paclitaxel. Pharmaceutics, 2019; 11(11):562; doi: 10.3390/pharmaceutics11110562
